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The Abstract is incorrect in Pubmed.
Cell-free (cf) DNA in the plasma of cancer patients offers an easily ob-
tainable source of biologic material for mutation analysis. Plasma samples 
from 157 patients with advanced cancers who progressed on systemic ther-
apy were tested for 21 mutations in BRAF, EGFR, KRAS, and PIK3CA using 
the BEAMing method and results were compared to mutation analysis of ar-
chival tumor tissue from a CLIA-certified laboratory obtained as standard of 
care from diagnostic or therapeutic procedures. Results were concordant for 
archival tissue and plasma cfDNA in 91% cases for BRAF mutations (kappa = 
0.75, 95% confidence interval [CI] 0.63 - 0.88), in 99% cases for EGFR mu-
tations (kappa = 0.90, 95% CI 0.71- 1.00), in 83% cases for KRAS mutations 
(kappa = 0.67, 95% CI 0.54 - 0.80) and in 91% cases for PIK3CA mutations 
(kappa = 0.65, 95% CI 0.46 - 0.85). Patients (n = 41) with > 1% of KRAS 
mutant cfDNA had a shorter median survival compared to 20 patients with 
1% of mutant cfDNA (BRAF, EGFR, KRAS, or PIK3CA) had a shorter median 
survival compared to 33 patients with </= 1% of mutant cfDNA (5.5 vs. 9.8 
months, p = 0.001), which was confirmed in multivariable analysis.
The corrected Abstract is provided here.
Cell-free (cf) DNA in the plasma of cancer patients offers an easily ob-
tainable source of biologic material for mutation analysis. Plasma samples 
from 157 patients with advanced cancers who progressed on systemic ther-
apy were tested for 21 mutations in BRAF, EGFR, KRAS, and PIK3CA using 
the BEAMing method and results were compared to mutation analysis of ar-
chival tumor tissue from a CLIA-certified laboratory obtained as standard of 
care from diagnostic or therapeutic procedures. Results were concordant for 
archival tissue and plasma cfDNA in 91% cases for BRAF mutations (kappa 
= 0.75, 95% confidence interval [CI] 0.63 – 0.88), in 99% cases for EGFR 
mutations (kappa = 0.90, 95% CI 0.71– 1.00), in 83% cases for KRAS muta-
tions (kappa = 0.67, 95% CI 0.54 – 0.80) and in 91% cases for PIK3CA mu-
tations (kappa = 0.65, 95% CI 0.46 – 0.85). Patients (n = 41) with > 1% of 
KRAS mutant cfDNA had a shorter median survival compared to 20 patients 
with </= 1% of KRAS mutant DNA (4.8 vs. 7.3 months, p = 0.008). Similarly, 
67 patients with > 1% of mutant cfDNA (BRAF, EGFR, KRAS, or PIK3CA) had 
a shorter median survival compared to 33 patients with </= 1% of mutant 
cfDNA (5.5 vs. 9.8 months, p = 0.001), which was confirmed in multivariable 
analysis.
